Siemens Healthineers has announced the Food and Drug Administration’s (FDA) premarket approval for its Mammomat B.brilliant, a newly redesigned mammography platform featuring advanced tomosynthesis technology. This innovative system represents the first major redesign in over a decade and integrates new three-dimensional image acquisition and reconstruction capabilities alongside established features for full-field digital mammography, breast biopsy, and titanium contrast-enhanced mammography. The Mammomat B.brilliant enhances patient comfort and ergonomics while streamlining user workflows, marking a significant advancement in breast cancer screening.
The Mammomat B.brilliant is distinguished by its 50-degree wide-angle technology, which effectively addresses the challenges of overlapping breast tissue common in two-dimensional imaging, offering up to 3.5 times greater depth resolution. Its PlatinumTomo technology facilitates rapid 3D image acquisition in under five seconds, while UltraHD image reconstruction improves visualization and reduces metal artifacts. The system also introduces ergonomic features designed for both technologists and patients, including automated tube positioning and intelligent breast compression. Siemens Healthineers, a global leader in medical technology, aims to improve healthcare access and combat significant diseases, with revenues of approximately $23.6 billion reported in fiscal 2023.
